Article
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.
Nature medicine - 1 May 2026
Park Wungki, O'Connor Catherine A, Chou Joanne F, Hilmi Marc, Tarcan Zeynep, Schwartz Carly, Larsen Mary, Homsi Ramzi, Sivaprakasam Karthigayini, Umeda Shigeaki, Perry Maria A, Varghese Anna M, Yu Kenneth H, Balogun Fiyinfolu, Zervoudakis Alice, Katz Seth S, Kim Tae-Hyung, Zhao Ken, Richards Allison L, Lecomte Nicolas, Martin Muldoon Daniel, Karnoub Elias, Chatila Walid, Yang Jessica, El-Dika Imane, Rao Devika, Joshi Smita, Foote Michael B, Sugarman Ryan, Harding James J, Epstein Andrew S, Kelsen David, Chalassani Sree, Keane Fergus, Schoenfeld Joshua D, Singhal Anupriya, Diguglielmo Erin, Bandlamudi Chaitanya, Song Junmin, Ozkan Hulya Sahin, Hong Junguei, Zhang Haochen, Cardenas Agustin Iii, Lao Maria, Melchor Jerry, Shah Ronak, Kang Wenfei, Mazzoni Francesca, Soares Kevin, Donoghue Mark Ta, Santos Ernesto, Rolston Vineet, Reyngold Marsha, Wei Alice Chia-Chi, Tipping Murray, Basturk Olca, Berger Michael, Kihn Do Richard, Schattner Mark, Jarnagin William R, Riaz Nadeem, Balachandran Vinod, Pe'er Dana, Capanu Marinela, Iacobuzio-Donahue Christine, O'Reilly Eileen M
Abstract excerpt
Homologous recombination deficiency (HRD) arising from BRCA1or BRCA2 or PALB2 mutations confers sensitivity to platinum chemotherapy and PARP inhibition in pancreatic cancer (PC) and may enable prolonged disease control with immune checkpoint blockade (ICB). The phase 2 POLAR trial evaluated maintenance pembrolizumab plus olaparib following platinum-based chemotherapy in biomarker-stratified metastatic PC....
Read the complete abstract on PubMed